Overcoming Drug Resistance in ALK-Rearranged Lung Cancer

Mené sur 130 patients atteints d'un cancer du poumon non à petites cellules avec réarrangements du gène ALK et résistant au crizotinib, cet essai de phase I évalue la dose maximale tolérée du ceritinib, un nouvel inhibiteur d'ALK, ainsi que le taux de réponse globale au traitement

Résumé en anglais

Approximately 4 to 15% of lung adenocarcinomas harbor a genomic rearrangement in the anaplastic lymphoma kinase gene (ALK) that creates a gene fusion activating the tyrosine kinase ALK. Treatment of patients with ALK-rearranged lung cancer with the MET and ALK inhibitor crizotinib induces responses and confers a benefit in progression-free survival.6 In a nonrandomized registry study, crizotinib also improved overall survival.
Unfortunately, all patients who have ALK-rearranged lung cancer will have a relapse eventually, after a response that typically lasts for 8 months. Thus, drugs that are capable of suppressing the growth of recurrent tumors . . .